Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$8.44M, compared with -$7.99M a year earlier. Trailing-twelve-month operating income was -$29.97M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 4 analysts of -$17.36M (+41.2%) for the fiscal year ending Dec 2026, a step up from the +8.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.44M-16.8% QoQ
- Last fiscal yearDec 2025
- -$29.52M+8.1% YoY
- LTMMar 2026
- -$29.97M+3.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5.6% | -91.2% | -85.6 pp |
| 1 year | +8.1% | +41.2% | +33.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (29.52M) USD
- Year-over-year change
- +8.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.52M) | +8.1% |
| FY2024 | 2024-12-31 | (32.12M) | -54.6% |
| FY2023 | 2023-12-31 | (20.77M) | -15.1% |
| FY2022 | 2022-12-31 | (18.05M) | -101.1% |
| FY2021 | 2021-12-31 | (8.98M) | — |
Operating Income vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3.0% is the 8th highest of 10, against a peer median of +23.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $38.18M USD | +166.8% | — | 14.9% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | -CA$11.99M CAD | +23.1% | — | 65.3% |
| LTM Mar 2026 | -$29.97M USD | +3.0% | — | — | |
| LTM Mar 2026 | -$52.03M USD | +2.4% | — | 1322.6% | |
CBUSCibus, Inc. | LTM Mar 2026 | -$58.96M USD | +77.4% | — | 1375.7% |
| LTM Mar 2026 | -$60.34M USD | +23.7% | — | — | |
| LTM Mar 2026 | -$66.57M USD | +49.8% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.35M USD | +11.6% | — | — |
| LTM Mar 2026 | -$83.66M USD | +5.8% | — | — | |
| LTM Mar 2026 | -$109.64M USD | -8.6% | — | — | |
| Peer median (excluding UNCY) | — | +23.1% | — | 694.0% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 951K | 675K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 572K |
| Gross Profit | 0 | 951K | 675K | 0 | (572K) |
| Gross Margin | — | 100.0% | 100.0% | — | — |
| Research & Development | 6.08M | 12.44M | 12.9M | 20.01M | 9.12M |
| Selling, General & Admin | 2.9M | 6.57M | 8.55M | 12.1M | 20.4M |
| Operating Expenses | 8.98M | 19M | 21.45M | 32.12M | 28.95M |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| EBITDA | (9.38M) | (17.89M) | (30.18M) | (36.23M) | (25.91M) |
| EBITDA Margin | — | -1881.3% | -4470.8% | — | — |
| Operating Income | (8.98M) | (18.05M) | (20.77M) | (32.12M) | (29.52M) |
| Operating Margin | — | -1898.2% | -3077.6% | — | — |
| Interest Income | 0 | 0 | 615K | 1.26M | 1.01M |
| Interest Expense | 628K | 6K | 82K | 71K | 71K |
| Other Income / Expenses | (1.04M) | (6K) | (9.77M) | (4.61M) | 2.96M |
| Income Before Tax | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Pre-Tax Margin | — | -1898.8% | -4525.0% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Net Margin | — | -1898.8% | -4525.0% | — | — |
| EPS (Basic) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| EPS (Diluted) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| Weighted Avg Shares | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
| Weighted Avg Shares (Diluted) | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.